Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Feb;67(2):406–414.

Dissociation between onset of natural killer E-rosette forming cells and of T3-positive cells following HLA-mismatched T cell depleted bone marrow transplantation.

J P De Villartay, F Le Deist, C Griscelli, A Fischer
PMCID: PMC1542578  PMID: 3301094

Abstract

We have studied immunological reconstitution following partially HLA-incompatible T cell depleted bone marrow transplantation, compared with reconstitution following HLA identical T cell depleted and HLA identical untreated bone marrow transplantation. We often observed an early emergence of E-rosette forming cells that were T3 negative and displayed strong natural killer activity in the first group of patients. This activity was shown with fresh leucocytes as well as interleukin 2 grown cells. The appearance of T3+ cells was delayed in this situation compared to that observed in HLA identical bone marrow transplantation. The delay in T3+ cell differentiation and in cellular immune function development probably explains why NK rosette forming cells are early detected within 3-4 months following HLA mismatched bone marrow transplantation. This NK subset is likely to be present at an early stage in all types of bone marrow transplantation, but is most commonly observed simultaneously with the T3+ cells in HLA identical untreated bone marrow transplantation. The respective role of T cell depletion and HLA incompatibility in this phenomenon are discussed while patients' conditioning, cyclosporine A and graft-versus-host disease have been shown to be irrelevant for the dissociation between NK E-rosette forming cells and T3+ subset onsets.

Full text

PDF
406

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ault K. A., Antin J. H., Ginsburg D., Orkin S. H., Rappeport J. M., Keohan M. L., Martin P., Smith B. R. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med. 1985 Jun 1;161(6):1483–1502. doi: 10.1084/jem.161.6.1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Breard J., Reinherz E. L., Kung P. C., Goldstein G., Schlossman S. F. A monoclonal antibody reactive with human peripheral blood monocytes. J Immunol. 1980 Apr;124(4):1943–1948. [PubMed] [Google Scholar]
  3. De Villartay J. P., Griscelli C., Fischer A. Self-tolerance to host and donor following HLA-mismatched bone marrow transplantation. Eur J Immunol. 1986 Feb;16(2):117–122. doi: 10.1002/eji.1830160202. [DOI] [PubMed] [Google Scholar]
  4. Dokhelar M. C., Wiels J., Lipinski M., Tetaud C., Devergie A., Gluckman E., Tursz T. Natural killer cell activity in human bone marrow recipients: early reappearance of peripheral natural killer activity in graft-versus-host disease. Transplantation. 1981 Jan;31(1):61–65. doi: 10.1097/00007890-198101000-00014. [DOI] [PubMed] [Google Scholar]
  5. Fischer A., Durandy A., de Villartay J. P., Vilmer E., Le Deist F., Gérota I., Griscelli C. HLA-haploidentical bone marrow transplantation for severe combined immunodeficiency using E rosette fractionation and cyclosporine. Blood. 1986 Feb;67(2):444–449. [PubMed] [Google Scholar]
  6. Friedrich W., Goldmann S. F., Vetter U., Fliedner T. M., Heymer B., Peter H. H., Reisner Y., Kleihauer E. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet. 1984 Apr 7;1(8380):761–764. doi: 10.1016/s0140-6736(84)91277-7. [DOI] [PubMed] [Google Scholar]
  7. Garland J. M., Crompton S. A preliminary report: preparations containing Interleukin-3 (IL-3) promote proliferation of multipotential stem cells (CFUs) in the mouse. Exp Hematol. 1983 Sep;11(8):757–761. [PubMed] [Google Scholar]
  8. Glucksberg H., Storb R., Fefer A., Buckner C. D., Neiman P. E., Clift R. A., Lerner K. G., Thomas E. D. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974 Oct;18(4):295–304. doi: 10.1097/00007890-197410000-00001. [DOI] [PubMed] [Google Scholar]
  9. Hemler M. E., Malissen B., Rebai N., Liabeuf A., Mawas C., Kourilsky F. M., Strominger J. L. A 55,000 Mr surface antigen on activated human T lymphocytes defined by a monoclonal antibody. Hum Immunol. 1983 Oct;8(2):153–165. doi: 10.1016/0198-8859(83)90010-1. [DOI] [PubMed] [Google Scholar]
  10. Hercend T., Meuer S., Brennan A., Edson M. A., Acuto O., Reinherz E. L., Schlossman S. F., Ritz J. Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med. 1983 Nov 1;158(5):1547–1560. doi: 10.1084/jem.158.5.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kenny A. B., Hitzig W. H. Bone marrow transplantation for severe combined immunodeficiency disease. Reported from 1968 to 1977. Eur J Pediatr. 1979 Jun 28;131(3):155–177. doi: 10.1007/BF00538940. [DOI] [PubMed] [Google Scholar]
  12. Lipinski M., Virelizier J. L., Tursz T., Griscelli C. Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production. Eur J Immunol. 1980 Apr;10(4):246–249. doi: 10.1002/eji.1830100405. [DOI] [PubMed] [Google Scholar]
  13. Ortaldo J. R., Sharrow S. O., Timonen T., Herberman R. B. Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol. 1981 Dec;127(6):2401–2409. [PubMed] [Google Scholar]
  14. Reinherz E. L., Geha R., Rappeport J. M., Wilson M., Penta A. C., Hussey R. E., Fitzgerald K. A., Daley J. F., Levine H., Rosen F. S. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci U S A. 1982 Oct;79(19):6047–6051. doi: 10.1073/pnas.79.19.6047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reinherz E. L., Kung P. C., Goldstein G., Schlossman S. F. A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2. J Immunol. 1980 Mar;124(3):1301–1307. [PubMed] [Google Scholar]
  16. Reinherz E. L., Kung P. C., Goldstein G., Schlossman S. F. A monoclonal antibody with selective reactivity with functionally mature human thymocytes and all peripheral human T cells. J Immunol. 1979 Sep;123(3):1312–1317. [PubMed] [Google Scholar]
  17. Reinherz E. L., Parkman R., Rappeport J., Rosen F. S., Schlossman S. F. Aberrations of suppressor T cells in human graft-versus-host disease. N Engl J Med. 1979 May 10;300(19):1061–1068. doi: 10.1056/NEJM197905103001901. [DOI] [PubMed] [Google Scholar]
  18. Reisner Y., Kapoor N., Kirkpatrick D., Pollack M. S., Cunningham-Rundles S., Dupont B., Hodes M. Z., Good R. A., O'Reilly R. J. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983 Feb;61(2):341–348. [PubMed] [Google Scholar]
  19. Saxon A., McIntyre R. E., Stevens R. H., Gale R. P. Lymphocyte dysfunction in chronic graft-versus-host disease. Blood. 1981 Oct;58(4):746–751. [PubMed] [Google Scholar]
  20. Slovin S. F., Schooley R. T., Thorley-Lawson D. A. Analysis of cellular immune response to EBV by using cloned T cell lines. J Immunol. 1983 May;130(5):2127–2132. [PubMed] [Google Scholar]
  21. Tsoi M. S., Storb R., Dobbs S., Kopecky K. J., Santos E., Weiden P. L., Thomas E. D. Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. J Immunol. 1979 Nov;123(5):1970–1976. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES